Product Program year 2025 Source: CMS Open Payments

Albutein

Biological Critical Care Medicine

NDC 68516-5216-2

Open in the dashboard

General payments

$459,635

305 payments

Research payments

$8,364,687

879 payments

Through program year 2025, $459,635 in general payments and $8,364,687 in research payments were reported against Albutein (Critical Care Medicine).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

14 rows
Year Kind Amount Payments
2025 General $3,737 5
2025 Research $778,941 73
2024 General $29,101 4
2024 Research $1,008,918 105
2023 General $17,896 12
2023 Research $881,729 104
2022 General $89,773 35
2022 Research $1,620,571 192
2021 General $32,285 10
2021 Research $559,387 92
2020 General $105,142 71
2020 Research $1,264,940 175
2019 General $181,701 168
2019 Research $2,250,201 138

Breakdown

Who paid General payments · program years 2019–2025
  1. Grifols Shared Services North America, Inc. $304,928 130 payments
  2. Grifols Biologicals LLC $107,439 100 payments
  3. Grifols, S.A. $33,896 17 payments
  4. Grifols Therapeutics LLC $11,454 19 payments
  5. Grifols USA, LLC $1,919 39 payments
Top recipients General payments · program year 2025
  1. Gregory Martin Pulmonary Disease · Atlanta, GA $3,489 93% · 1 payment
  2. Tarek Hassanein Hepatology · Coronado, CA $125 3% · 1 payment
  3. Michael Fallon Gastroenterology · Houston, TX $60 2% · 1 payment
  4. Rohit Katial Allergy & Immunology · Denver, CO $31 <1% · 1 payment
  5. Anas Hadeh Pulmonary Disease · Weston, FL $31 <1% · 1 payment

Each share is of general payments naming this product in 2025.

Specialties paid General payments · program year 2025
  1. Pulmonary Disease Internal Medicine $3,521 94% · 2 practitioners
  2. Hepatology Internal Medicine $125 3% · 1 practitioner
  3. Gastroenterology Internal Medicine $60 2% · 1 practitioner
  4. Allergy & Immunology $31 <1% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2025
  1. Georgia $3,489 93% · 1 recipient
  2. California $125 3% · 1 recipient
  3. Texas $60 2% · 1 recipient
  4. Colorado $31 <1% · 1 recipient
  5. Florida $31 <1% · 1 recipient

Each share is of general payments naming this product in 2025 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

15

Prescriptions dispensed, refills included

Drug cost

$2,000

Paid at the pharmacy, in all

Prescribers

1

With 11 or more claims of it

Medicare Part D drugs matched to Albutein, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Albutein Albumin Human Same name 1 15 $2,000

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

1 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Jauvid Ayadi Internal Medicine FL 15 $2,000 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

305 general · 879 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record